Vol. 3, Issue 1 (supplement), 2025June 30, 2025 EDT
The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer
The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer
1.
Oyeniyi J, Kumari A, Mohammad G, Zhao Y, Marcus S, Prakash C. The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer. MI Medical Education and Health Bulletin. 2025;3(1 (supplement)):A115. doi:10.69735/001c.141316